Tuftsin analog raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-01-18. Anything still debated is marked as such rather than presented as settled.
Selank is a hydrophilic peptide and dissolves readily in water and in aqueous buffers. The lyophilised powder is typically a white to off-white solid. Because short peptides are prone to hydrolysis and oxidation, handling benefits from limiting exposure to heat, moisture and strong light. Working solutions are commonly prepared in sterile water or saline, and repeated freeze-thaw cycles are avoided to reduce aggregation and loss of activity. These practices reflect general laboratory convention rather than published stability specifications.
Dry powder is normally held at -20 degrees Celsius or lower, in a sealed container with desiccant and protection from light. Reconstituted solutions are usually kept at 2 to 8 degrees Celsius for short periods and frozen for longer ones. Proline residues at several positions are generally associated with some resistance to peptidase attack, but chemical stability still declines at neutral to alkaline pH and at elevated temperature. Exact shelf-life figures are product-specific and are not standardised across suppliers.
Lyophilized Selank, the dry powder form, is generally stored frozen at minus 20 degrees Celsius or colder for long-term keeping. The solid is hygroscopic and should stay sealed, dry, and protected from light. Once dissolved, the peptide is less stable and is usually held refrigerated at 2 to 8 degrees Celsius for short periods. Repeated freezing and thawing is avoided because it can promote aggregation and loss of activity. Buffers and pH choice also affect how long a solution remains usable.
Solubility behavior is a practical concern for handling. Selank dissolves readily in water and in common aqueous buffers, which simplifies preparation of working solutions. The choice of solvent, ionic strength, and pH can influence aggregation over time, particularly at higher concentrations. Aqueous solutions are typically sterile-filtered before use. Because stability depends on several variables, storage and handling notes should be treated as general guidance rather than fixed rules, and specific values are best confirmed against a certificate of analysis for each batch.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilised solid form |
| Solubility class | Freely soluble in water | Hydrophilic heptapeptide |
| Dry storage temperature | -20 degrees Celsius or lower | Sealed, desiccated, protected from light |
| Solution storage | 2 to 8 degrees Celsius short term | Avoid repeated freeze-thaw cycles |
| Common identification method | Reversed-phase HPLC with mass spectrometry | Confirms purity and molecular mass |
Naming for this compound is not fully standardised in English sources. The spelling Selanc appears in some transliterations, and catalogue entries may instead list the peptide sequence itself as the identifier. Reference material sometimes groups it with other short synthetic peptides studied for behavioural effects, which can create confusion when citations are compared. Distinguishing the exact sequence from related tuftsin analogues is therefore a practical first step when reviewing any dataset or specification sheet.
Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro, frequently abbreviated as TKPRPGP. It was designed as a structural analogue of tuftsin, a naturally occurring tetrapeptide released by enzymatic cleavage of the immunoglobulin heavy chain. The two additional proline residues at the C-terminal end extend the parent chain and change how the molecule behaves in solution. The free peptide has a calculated molecular mass of approximately 751.9 g/mol and is generally supplied as a lyophilised white to off-white powder.
Development work on the compound began in the 1980s and 1990s at the Institute of Molecular Genetics in Moscow, within the same research programme that produced the peptide Semax. Early investigators sought a tuftsin derivative with improved resistance to enzymatic breakdown and with activity in the central nervous system after peripheral administration. Most of the primary literature from this period was published in Russian, a factor that still shapes how easily the findings can be checked by outside groups.
Selank is not a naturally occurring peptide and has no known endogenous counterpart in human physiology. Russian-language sources frequently call it TP-7, while English-language sources use the name Selank almost exclusively. Database indexing is uneven, partly because early reports appeared in regional journals that are not widely cataloged. Some summaries describe the material as a tuftsin analog and others as a synthetic heptapeptide; the labels overlap rather than conflict. Citing the primary sequence resolves ambiguity more reliably than the research or trade name alone.
Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro, written TKPRPGP in one-letter notation. Its structure consists of the immunomodulatory tetrapeptide tuftsin, Thr-Lys-Pro-Arg, extended at the carboxyl terminus by a Pro-Gly-Pro segment. The molecular formula is commonly given as C33H57N11O9, corresponding to a monoisotopic mass near 751.4 Da and an average molecular mass near 751.9 Da. All seven residues are proteinogenic amino acids, and the molecule carries no modified side chains or non-natural linkages.
=== Radiology === Radiologically, the main feature required for a confident diagnosis of UIP is honeycomb change in the periphery and the lower portions (bases) of the lungs. On high-resolution computed tomography (HRCT), the following categories, depending on imaging findings, have been recommended by a collaborative effort by the American Thoracic Society, European Respiratory Society, Japanese Respiratory Society, and the Latin American Thoracic Society:
Opiorphin is an endogenous chemical compound first isolated from human saliva. Initial research with mice shows the compound has a painkilling effect greater than that of morphine. It works by stopping the normal breakup of enkephalins, natural pain-killing opioids in the spinal cord. It is a relatively simple molecule consisting of a five-amino acid polypeptide, Gln-Arg-Phe-Ser-Arg (QRFSR). Opiorphin pentapeptide originates from the N-terminal region of the protein PROL1 (proline-rich, lacrimal 1). Opiorphin inhibits three proteases: neutral ecto-endopeptidase (MME), ecto-aminopeptidase N (ANPEP) and perhaps also a dipeptidyl peptidase DPP3. Such action extends the duration of enkephalin effect where the natural pain killers are released physiologically in response to specific potentially painful stimuli, in contrast with administration of narcotics, which floods the entire body and causes many undesirable adverse reactions, including addiction liability and constipation. In addition, opiorphin may exert anti-depressive and antipanic action. Therapeutic application of opiorphin in humans would require modifying the molecule to avoid its rapid degradation in the intestine and its poor penetration of the blood–brain barrier. This modification is done in the body by transformation of N-terminal glutamine into pyroglutamate. This form preserves the analgesic properties of opiorphin but with increased pharmaceutical stability.
== Mechanism of action == Icotrokinra is a targeted oral peptide that selectively binds to and blocks the interleukin 23 receptor (IL-23R), thereby inhibiting IL-23-mediated signaling. The drug demonstrates high affinity for the human IL-23 receptor with a dissociation constant (KD) of 7.1 pM and inhibits IL-23-induced STAT3 phosphorylation in peripheral blood mononuclear cells with an IC50 of 5.6 pM. The IL-23 pathway plays a central role in the inflammatory cascade underlying various autoimmune conditions, particularly those involving Th17 cells. Unlike injectable biologics that target IL-23 or its receptor, icotrokinra offers the convenience of oral administration while maintaining selective receptor binding.
The market square also hosts the former washhouse and public baths of the neighbourhood, among the oldest examples of their kind in Turin (1905). One of the main thoroughfares crossing Borgo San Secondo is Via Sacchi, which serves as an ideal gate to the city centre: its Serlian arcades on the west side of the street (the east side is enclosed by Porta Nuova railway station service buildings) host some significant boutiques and hotels, such as the historic Pfatisch pastry shop and the Turin Palace Hotel (totally refurbished and reopened in 2015). South of Via Sacchi, Ospedale Mauriziano is one of the ancient and major hospitals of the city. Going further southwards, it is possible to appreciate an interesting residential cluster of old public housing gravitating around Via Arquata.
Sources: en.wikipedia.org
With security largely under the purview of the BPC, corporate control of the park has meant that Bryant Park received passive-recreation amenities, while excluding active sports that might cater to a broader urban public. The BPC added a custom-built carousel in 2002 and revived the tradition of an open-air library, the Reading Room, in 2003. In July 2002, the park launched a public wireless network, making the park the first in New York City to formally offer free Wi-Fi access to visitors. The Wi-Fi system was subsequently upgraded in 2008. Furthermore, the Pond, a free-admission ice skating rink, opened in the park in 2005. The park's public restrooms were renovated in 2006 and in 2017. The dramatic rise in real estate values in the area around Bryant Park, as well as new construction in adjacent areas, was a consequence of the park's improvements. By 1993, the surrounding region had become a highly desirable office area, and formerly vacant office space around the park was being filled quickly. By the first decade of the 21st century, nearby buildings and businesses were also using names that referred to the park. This was shown by the then-new Bank of America Tower skyscraper at the park's northeast corner using the address "One Bryant Park", as well as the growing trend of Bryant Park vanity addresses, including 3, 4, 5, and 7 Bryant Park. National Public Radio, located just south of the park, also named a now-defunct talk show the "Bryant Park Project" upon the show's 2007 launch.
== Zailin == Zailin is the brand name for the company's line of generic prescription amoxicillin antibiotics, which includes capsules, dispersible tablets, granules and injection. During the year ended December 31, 2007, revenues of Zailin accounted for 21% of the company's product revenues.
Arizona, 5.53% (187,382 votes) – 11 electoral votes Virginia, 5.78% (260,310 votes) – 13 electoral votes New Jersey, 5.91% (252,498 votes) – 14 electoral votes New Mexico, 6.00% (55,411 votes) – 5 electoral votes Maine, 6.94% (57,514 votes) – 2 electoral votes Maine's 2nd congressional district, 9.03% (33,297 votes) – 1 electoral vote Red denotes states or congressional districts won by Republican Donald Trump; Blue denotes those won by Democrat Kamala Harris.
=== EC 1.14.13 With NADH or NADPH as one donor, and incorporation of one atom of oxygen into the other donor === EC 1.14.13.1: salicylate 1-monooxygenase EC 1.14.13.2: 4-hydroxybenzoate 3-monooxygenase EC 1.14.13.3: Now EC 1.14.14.9, 4-hydroxyphenylacetate 3-monooxygenase EC 1.14.13.4: melilotate 3-monooxygenase EC 1.14.13.5: imidazoleacetate 4-monooxygenase EC 1.14.13.6: orcinol 2-monooxygenase EC 1.14.13.7: phenol 2-monooxygenase EC 1.14.13.8: flavin-containing monooxygenase EC 1.14.13.9: kynurenine 3-monooxygenase EC 1.14.13.10: 2,6-dihydroxypyridine 3-monooxygenase EC 1.14.13.11: Now EC 1.14.14.91, trans-cinnamate 4-monooxygenase EC 1.14.13.12: Now EC 1.14.14.92, benzoate 4-monooxygenase EC 1.14.13.13: Now classified as EC 1.14.15.18, calcidiol 1-monooxygenase EC 1.14.13.14: trans-cinnamate 2-monooxygenase EC 1.14.13.15: Now EC 1.14.15.15, cholestanetriol 26-monooxygenase EC 1.14.13.16: cyclopentanone monooxygenase EC 1.14.13.17: Now EC 1.14.14.23, cholesterol 7α-monooxygenase EC 1.14.13.18: 4-hydroxyphenylacetate 1-monooxygenase EC 1.14.13.19: taxifolin 8-monooxygenase EC 1.14.13.20: 2,4-dichlorophenol 6-monooxygenase EC 1.14.13.21: Now EC 1.14.14.82, flavonoid 3′-monooxygenase EC 1.14.13.22: cyclohexanone monooxygenase EC 1.14.13.23: 3-hydroxybenzoate 4-monooxygenase EC 1.14.13.24: 3-hydroxybenzoate 6-monooxygenase EC 1.14.13.25: methane monooxygenase (soluble) EC 1.14.13.26: Now classified as EC 1.14.18.4, phosphatidylcholine 12-monooxygenase EC 1.14.13.27: 4-aminobenzoate 1-monooxygenase EC 1.14.13.28: Now EC 1.14.14.93, 3,9-dihydroxypterocarpan 6a-monooxygenase EC 1.14.13.29: 4-nitrophenol 2-monooxygenase EC 1.14.13.30: Now EC 1.14.14.94, leukotriene-B4 20-monooxygenase EC 1.14.13.31: 2-nitrophenol 2-monooxygenase EC 1.14.13.32: albendazole monooxygenase EC 1.14.13.33: 4-hydroxybenzoate 3-monooxygenase (NAD(P)H) EC 1.14.13.34: leukotriene-E4 20-monooxygenase EC 1.14.13.35: anthranilate 3-monooxygenase (deaminating) EC 1.14.13.36: Now EC 1.14.14.96, 5-O-(4-coumaroyl)-D-quinate 3′-monooxygenase EC 1.14.13.37: Now EC 1.14.14.97, methyltetrahydroprotoberberine 14-monooxygenase EC 1.14.13.38: anhydrotetracycline monooxygenase EC 1.14.13.39: nitric-oxide synthase EC 1.14.13.40: anthraniloyl-CoA monooxygenase EC 1.14.13.41: Now EC 1.14.14.36, tyrosine N-monooxygenase EC 1.14.13.42: The activity is covered by EC 1.14.13.68, 4-hydroxyphenylacetaldehyde oxime monooxygenase EC 1.14.13.43: questin monooxygenase EC 1.14.13.44: 2-hydroxybiphenyl 3-monooxygenase EC 1.14.13.45: Now EC 1.14.18.2, CMP-N-acetylneuraminate monooxygenase EC 1.14.13.46: (-)-menthol monooxygenase EC 1.14.13.47: Now EC 1.14.14.99, (S)-limonene 3-monooxygenase EC 1.14.13.48: Now classified as EC 1.14.14.51, (S)-limonene 6-monooxygenase EC 1.14.13.49: Now classified as EC 1.14.14.52, (S)-limonene 7-monooxygenase EC 1.14.13.50: pentachlorophenol monooxygenase EC 1.14.13.51: 6-oxocineole dehydrogenase EC 1.14.13.52: Now EC 1.14.14.88, isoflavone 3′-hydroxylase EC 1.14.13.53: Now EC 1.14.14.89, 4′-methoxyisoflavone 2′-hydroxylase EC 1.14.13.54: ketosteroid monooxygenase EC 1.14.13.55: Now EC 1.14.14.98, protopine 6-monooxygenase EC 1.14.13.56: Now EC 1.14.14.100, dihydrosanguinarine 10-monooxygenase EC 1.14.13.57: Now EC 1.14.14.101, dihydrochelirubine 12-monooxygenase EC 1.14.13.58: benzoyl-CoA 3-monooxygenase EC 1.14.13.59: L-lysine N6-monooxygenase (NADPH) EC 1.14.13.60: Now included with EC 1.14.13.100, 25-hydroxycholesterol 7α-hydroxylase EC 1.14.13.61: 2-hydroxyquinoline 8-monooxygenase EC 1.14.13.62: 4-hydroxyquinoline 3-monooxygenase EC 1.14.13.63: 3-hydroxyphenylacetate 6-hydroxylase EC 1.14.13.64: 4-hydroxybenzoate 1-hydroxylase EC 1.14.13.65: deleted EC 1.14.13.66: 2-hydroxycyclohexanone 2-monooxygenase EC 1.14.13.67: Now EC 1.14.14.55, quinine 3-monooxygenase EC 1.14.13.68: Now EC 1.14.14.37, 4-hydroxyphenylacetaldehyde oxime monooxygenase EC 1.14.13.69: alkene monooxygenase EC 1.14.13.70: Now EC 1.14.14.154, sterol 14α-demethylase EC 1.14.13.71: Now EC 1.14.14.102, N-methylcoclaurine 3′-monooxygenase EC 1.14.13.72: Now classified as EC 1.14.18.9, methylsterol monooxygenase EC 1.14.13.73: Now EC 1.14.14.103, tabersonine 16-hydroxylase EC 1.14.13.74: Now EC 1.14.14.85, 7-deoxyloganin 7-hydroxylase EC 1.14.13.75: Now EC 1.14.14.104, vinorine hydroxylase EC 1.14.13.76: Now EC 1.14.14.105, taxane 10β-hydroxylase EC 1.14.13.77: Now EC 1.14.14.106, taxane 13α-hydroxylase EC 1.14.13.78: Now EC 1.14.14.86, ent-kaurene monooxygenase EC 1.14.13.79: Now EC 1.14.14.107, ent-kaurenoic acid oxidase EC 1.14.13.80: Now classified as EC 1.14.14.53, (R)-limonene 6-monooxygenase EC 1.14.13.81: magnesium-protoporphyrin IX monomethyl ester (oxidative) cyclase EC 1.14.13.82: vanillate monooxygenase EC 1.14.13.83: precorrin-3B synthase EC 1.14.13.84: 4-hydroxyacetophenone monooxygenase EC 1.14.13.85: Now EC 1.14.14.135, glyceollin synthase EC 1.14.13.86: The activity is covered by EC 1.14.14.87, 2-hydroxyisoflavanone synthase EC 1.14.13.87: Now EC 1.14.14.140, licodione synthase] EC 1.14.13.88: Now EC 1.14.14.81, flavanoid 3,5-hydroxylase EC 1.14.13.89: Now EC 1.14.14.90, isoflavone 2-hydroxylase EC 1.14.13.90: Now EC 1.14.15.21, zeaxanthin epoxidase EC 1.14.13.91: Now EC 1.14.14.136, deoxysarpagine hydroxylase EC 1.14.13.92: phenylacetone monooxygenase EC 1.14.13.93: Now EC 1.14.14.137, (+)-abscisic acid 8-hydroxylase EC 1.14.13.94: Now EC 1.14.14.138, lithocholate 6β-hydroxylase EC 1.14.13.95: Now included with EC 1.14.14.139, 5β-cholestane-3α,7α-diol 12α-hydroxylase EC 1.14.13.96: Now EC 1.14.14.139, 5β-cholestane-3α,7α-diol 12α-hydroxylase EC 1.14.13.97: Now EC 1.14.14.57, taurochenodeoxycholate 6α-hydroxylase EC 1.14.13.98: Now EC 1.14.14.25, cholesterol 24-hydroxylase EC 1.14.13.99: Now EC 1.14.14.26, 24-hydroxycholesterol 7α-hydroxylase EC 1.14.13.100: Now classified as EC 1.14.14.29, 25/26-hydroxycholesterol 7α-hydroxylase EC 1.14.13.101: senecionine N-oxygenase EC 1.14.13.102: Now EC 1.14.14.141, psoralen synthase EC 1.14.13.103: Now EC 1.14.14.142, 8-dimethylallylnaringenin 2-hydroxylase EC 1.14.13.104: Now EC 1.14.14.143, (+)-menthofuran synthase EC 1.14.13.105: monocyclic monoterpene ketone monooxygenase EC 1.14.13.106: now classified as EC 1.14.15.39, epi-isozizaene 5-monooxygenase. EC 1.14.13.107: limonene 1,2-monooxygenase EC 1.14.13.108: Now EC 1.14.14.144, abieta-7,13-diene hydroxylase EC 1.14.13.109: Now EC 1.14.14.145, abieta-7,13-dien-18-ol hydroxylase EC 1.14.13.110: Now EC 1.14.14.146, geranylgeraniol 18-hydroxylase EC 1.14.13.111: methanesulfonate monooxygenase EC 1.14.13.112: Now EC 1.14.14.147, 3-epi-6-deoxocathasterone 23-monooxygenase EC 1.14.13.113: FAD-dependent urate hydroxylase EC 1.14.13.114: 6-hydroxynicotinate 3-monooxygenase EC 1.14.13.115: Now EC 1.14.14.148, angelicin synthase EC 1.14.13.116: Now EC 1.14.14.174, geranylhydroquinone 3-hydroxylase EC 1.14.13.117: Now EC 1.14.14.39, isoleucine N-monooxygenase EC 1.14.13.118: Now EC 1.14.14.38, valine N-monooxygenase EC 1.14.13.119: Now EC 1.14.14.149, 5-epiaristolochene 1,3-dihydroxylase EC 1.14.13.120: Now EC 1.14.14.150, costunolide synthase EC 1.14.13.121: Now EC 1.14.14.151, premnaspirodiene oxygenase EC 1.14.13.122: chlorophyllide-a oxygenase EC 1.14.13.123: Now EC 1.14.14.95, germacrene A hydroxylase EC 1.14.13.124: now classified as EC 1.14.14.40, phenylalanine N-monooxygenase EC 1.14.13.125: Now EC 1.14.14.156, tryptophan N-monooxygenase EC 1.14.13.126: Now EC 1.14.15.16, vitamin D3 24-hydroxylase EC 1.14.13.127: 3-(3-hydroxyphenyl)propanoate hydroxylase EC 1.14.13.128: 7-methylxanthine demethylase EC 1.14.13.129: Now EC 1.14.15.24, β-carotene 3-hydroxylase EC 1.14.13.130: pyrrole-2-carboxylate monooxygenase EC 1.14.13.131: dimethyl-sulfide monooxygenase EC 1.14.13.132: Now EC 1.14.14.17, squalene monooxygenase EC 1.14.13.133: Now EC 1.14.15.32, pentalenene oxygenase EC 1.14.13.134: Now EC 1.14.14.152, β-amyrin 11-oxidase EC 1.14.13.135: 1-hydroxy-2-naphthoate hydroxylase EC 1.14.13.136: Now EC 1.14.14.87, 2-hydroxyisoflavanone synthase EC 1.14.13.137: Now EC 1.14.14.153, indole-2-monooxygenase EC 1.14.13.138: Now EC 1.14.14.157, indolin-2-one monooxygenase EC 1.14.13.139: Now EC 1.14.14.109, 3-hydroxyindolin-2-one monooxygenase EC 1.14.13.140: Now EC 1.14.14.110, 2-hydroxy-1,4-benzoxazin-3-one monooxygenase. EC 1.14.13.141: Now EC 1.14.15.29, cholest-4-en-3-one 26-monooxygenase [(25S)-3-oxocholest-4-en-26-oate forming] EC 1.14.13.142: Now EC 1.14.15.30, 3-ketosteroid 9α-monooxygenase EC 1.14.13.143: Now EC 1.14.14.76 ent-isokaurene C2/C3-hydroxylase EC 1.14.13.144: Now EC 1.14.14.111, 9β-pimara-7,15-diene oxidase EC 1.14.13.145: Now EC 1.14.14.112, ent-cassa-12,15-diene 11-hydroxylase EC 1.14.13.146: taxoid 14β-hydroxylase EC 1.14.13.147: Now EC 1.14.14.182, taxoid 7β-hydroxylase EC 1.14.13.148: trimethylamine monooxygenase EC 1.14.13.149: phenylacetyl-CoA 1,2-epoxidase EC 1.14.13.150: Now EC 1.14.14.113, α-humulene 10-hydroxylase EC 1.14.13.151: Now EC 1.14.14.84, linalool 8-monooxygenase EC 1.14.13.152: Now EC 1.14.14.83, geraniol 8-hydroxylase EC 1.14.13.153: (+)-sabinene 3-hydroxylase EC 1.14.13.154: erythromycin 12-hydroxylase EC 1.14.13.155: α-pinene monooxygenase EC 1.14.13.156: Now EC 1.14.14.133, 1,8-cineole 2-endo-monooxygenase EC 1.14.13.157: Now EC 1.14.14.56, 1,8-cineole 2-exo-monooxygenase EC 1.14.13.158: Now EC 1.14.14.114, amorpha-4,11-diene 12-monooxygenase EC 1.14.13.159: Now EC 1.14.14.24, vitamin D 25-hydroxylase EC 1.14.13.160: (2,2,3-trimethyl-5-oxocyclopent-3-enyl)acetyl-CoA 1,5-monooxygenase EC 1.14.13.161: (+)-camphor 6-exo-hydroxylase EC 1.14.13.162: Now EC 1.14.14.108, 2,5-diketocamphane 1,2-monooxygenase EC 1.14.13.163: 6-hydroxy-3-succinoylpyridine 3-monooxygenase EC 1.14.13.164: withdrawn: see EC 1.13.11.65, carotenoid isomerooxygenase EC 1.14.13.165: Now classified as EC 1.14.14.47, nitric-oxide synthase (flavodoxin) EC 1.14.13.166: 4-nitrocatechol 4-monooxygenase EC 1.14.13.167: 4-nitrophenol 4-monooxygenase EC 1.14.13.168: indole-3-pyruvate monooxygenase EC 1.14.13.169: Now EC 1.14.18.5, sphingolipid C4-monooxygenase EC 1.14.13.170: pentalenolactone D synthase EC 1.14.13.171: neopentalenolactone D synthase EC 1.14.13.172: salicylate 5-hydroxylase EC 1.14.13.173: Now EC 1.14.14.115, 11-oxo-β-amyrin 30-oxidase EC 1.14.13.174: Now EC 1.14.14.116, averantin hydroxylase EC 1.14.13.175: Now EC 1.14.14.117, aflatoxin B synthase EC 1.14.13.176: Now EC 1.14.14.118, tryprostatin B 6-hydroxylase EC 1.14.13.177: Now EC 1.14.14.119, fumitremorgin C monooxygenase EC 1.14.13.178: methylxanthine N1-demethylase EC 1.14.13.179: methylxanthine N3-demethylase EC 1.14.13.180: aklavinone 12-hydroxylase EC 1.14.13.181: 13-deoxydaunorubicin hydroxylase EC 1.14.13.182: 2-heptyl-3-hydroxy-4(1H)-quinolone synthase EC 1.14.13.183: Now EC 1.14.14.120, dammarenediol 12-hydroxylase EC 1.14.13.184: Now EC 1.14.14.121, protopanaxadiol 6-hydroxylase EC 1.14.13.185: Now EC 1.14.15.33, pikromycin synthase EC 1.14.13.186: Now EC 1.14.15.34, 20-oxo-5-O-mycaminosyltylactone 23-monooxygenase EC 1.14.13.187: L-evernosamine nitrososynthase EC 1.14.13.188: Now EC 1.14.15.35, 6-deoxyerythronolide B hydroxylase EC 1.14.13.189: 5-methyl-1-naphthoate 3-hydroxylase EC 1.14.13.190: Now EC 1.14.14.175, ferruginol synthase EC 1.14.13.191: Now EC 1.14.14.70, ent-sandaracopimaradiene 3-hydroxylase EC 1.14.13.192: Now EC 1.14.14.122, oryzalexin E synthase EC 1.14.13.193: Now EC 1.14.14.123, oryzalexin D synthase EC 1.14.13.194: Now EC 1.14.14.78, phylloquinone ω-hydroxylase EC 1.14.13.195: L-ornithine N5-monooxygenase (NADPH) EC 1.14.13.196: L-ornithine N5-monooxygenase [NAD(P)H] EC 1.14.13.197: Now EC 1.14.14.124, dihydromonacolin L hydroxylase EC 1.14.13.198: Now EC 1.14.14.125, monacolin L hydroxylase EC 1.14.13.199: Now EC 1.14.14.79, docosahexaenoic acid ω-hydroxylase EC 1.14.13.200: tetracenomycin A2 monooxygenase-dioxygenase EC 1.14.13.201: Now EC 1.14.14.126, β-amyrin 28-monooxygenase EC 1.14.13.202: Now EC 1.14.14.127, methyl farnesoate epoxidase EC 1.14.13.203: Now EC 1.14.14.128, farnesoate epoxidase EC 1.14.13.204: Now EC 1.14.14.129, long-chain acyl-CoA ω-monooxygenase EC 1.14.13.205: Now EC 1.14.14.80, long-chain fatty acid ω-monooxygenase EC 1.14.13.206: Now EC 1.14.14.130, laurate 7-monooxygenase EC 1.14.13.207: Now EC 1.14.14.31, ipsdienol synthase EC 1.14.13.208: benzoyl-CoA 2,3-epoxidase EC 1.14.13.209: salicyloyl-CoA 5-hydroxylase EC 1.14.13.210: 4-methyl-5-nitrocatechol 5-monooxygenase EC 1.14.13.211: rifampicin monooxygenase EC 1.14.13.212: 1,3,7-trimethyluric acid 5-monooxygenase EC 1.14.13.213: Now EC 1.14.14.131, bursehernin 5-monooxygenase EC 1.14.13.214: Now EC 1.14.14.132, (–)-4′-demethyl-deoxypodophyllotoxin 4-hydroxylase EC 1.14.13.215: protoasukamycin 4-monooxygenase EC 1.14.13.216: asperlicin C monooxygenase EC 1.14.13.217: protodeoxyviolaceinate monooxygenase EC 1.14.13.218: 5-methylphenazine-1-carboxylate 1-monooxygenase EC 1.14.13.219: resorcinol 4-hydroxylase (NADPH) EC 1.14.13.220: resorcinol 4-hydroxylase (NADH) EC 1.14.13.221: Now EC 1.14.15.28, cholest-4-en-3-one 26-monooxygenase [(25R)-3-oxocholest-4-en-26-oate forming] EC 1.14.13.222: aurachin C monooxygenase/isomerase EC 1.14.13.223: 3-hydroxy-4-methylanthranilyl-[aryl-carrier protein] 5-monooxygenase EC 1.14.13.224: violacein synthase EC 1.14.13.225: F-actin monooxygenase EC 1.14.13.226: acetone monooxygenase (methyl acetate-forming) EC 1.14.13.227: propane 2-monooxygenase EC 1.14.13.228: jasmonic acid 12-hydroxylase EC 1.14.13.229: tert-butyl alcohol monooxygenase EC 1.14.13.230: butane monooxygenase (soluble) EC 1.14.13.231: tetracycline 11a-monooxygenase EC 1.14.13.232: 6-methylpretetramide 4-monooxygenase EC 1.14.13.233: 4-hydroxy-6-methylpretetramide 12a-monooxygenase EC 1.14.13.234: 5a,11a-dehydrotetracycline 5-monooxygenase EC 1.14.13.235: indole-3-acetate monooxygenase EC 1.14.13.236: toluene 4-monooxygenase EC 1.14.13.237: aliphatic glucosinolate S-oxygenase EC 1.14.13.238: dimethylamine monooxygenase EC 1.14.13.239: carnitine monooxygenase EC 1.14.13.240: 2-polyprenylphenol 6-hydroxylase EC 1.14.13.241: 5-pyridoxate monooxygenase EC 1.14.13.242: 3-hydroxy-2-methylpyridine-5-carboxylate monooxygenase EC 1.14.13.243: toluene 2-monooxygenase EC 1.14.13.244: phenol 2-monooxygenase (NADH) EC 1.14.13.245: assimilatory dimethylsulfide S-monooxygenase EC 1.14.13.246: 4β-methylsterol monooxygenase EC 1.14.13.247: stachydrine N-demethylase
=== Classification === Malignant peripheral nerve sheath tumors are a rare type of cancer that arise from the soft tissue that surrounds nerves. They are a type of sarcoma. Most malignant peripheral nerve sheath tumors arise from the nerve plexuses that distribute nerves into the limbs—the brachial and lumbar plexuses—or from nerves as they arise from the trunk.
Sources: en.wikipedia.org
Dry powder is normally held at -20 degrees Celsius or below in a sealed, light-protected container with desiccant. Brief room-temperature handling during weighing is generally tolerated. Storage instructions vary between suppliers, so the accompanying certificate of analysis should be followed.
Reversed-phase HPLC establishes purity, while mass spectrometry confirms the expected molecular mass. Sequence confirmation may use tandem mass spectrometry or peptide mapping. A certificate of analysis typically reports these results alongside the analytical method applied.
In Russia it is a registered medicine available by prescription. In many other countries it is not approved for human use and is supplied only as a research chemical. Import and possession rules differ by jurisdiction, and buyers are responsible for checking local requirements.
Reverse-phase HPLC is the usual method and gives a percentage purity value. Mass spectrometry then confirms the molecular mass. Together they provide a basic identity and purity profile for a lot.